Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Rene Geyeregger

dblp:270/8997 · DBLP profile ↗
← Back
1ranked-venue papers
0as first author
1since 2021 · last 2022
—ORCID · none

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 1 · 1 since 2021

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 100%

Topics — the 3 heaviest of 4, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology
cancer genomics
0.612022
nextNEOpi: a comprehensive pipeline for computational neoantigen prediction · Bioinform. 2022
Bioinformatics and computational biology › cancer genomics › somatic mutation analysis
cancer mutation analysis
0.612022
nextNEOpi: a comprehensive pipeline for computational neoantigen prediction · Bioinform. 2022
Bioinformatics and computational biology › immunoinformatics
neoantigen prediction
0.612022
nextNEOpi: a comprehensive pipeline for computational neoantigen prediction · Bioinform. 2022

Methods — techniques the papers use, named apart from their topics

sequencing data analysis · 0.6nextflow pipeline · 0.6
YearPublicationVenuePosition
2022 nextNEOpi: a comprehensive pipeline for computational neoantigen prediction
abstract
SUMMARY: Somatic mutations and gene fusions can produce immunogenic neoantigens mediating anticancer immune responses. However, their computational prediction from sequencing data requires complex computational workflows to identify tumor-specific aberrations, derive the resulting peptides, infer patients' Human Leukocyte Antigen types and predict neoepitopes binding to them, together with a set of features underlying their immunogenicity. Here, we present nextNEOpi (nextflow NEOantigen prediction pipeline) a comprehensive and fully automated bioinformatic pipeline to predict tumor neoantigens from raw DNA and RNA sequencing data. In addition, nextNEOpi quantifies neoepitope- and patient-specific features associated with tumor immunogenicity and response to immunotherapy. AVAILABILITY AND IMPLEMENTATION: nextNEOpi source code and documentation are available at https://github.com/icbi-lab/nextNEOpi. CONTACT: [email protected] or [email protected]. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Dietmar Rieder, Georgios Fotakis, Markus Ausserhofer, Rene Geyeregger, Wolfgang Paster, Zlatko Trajanoski, Francesca Finotello
Bioinform.4